NATIONAL PHARMA SOCIETY

2010-08-13T22:39:00.000-07:00

I Swear by the code of Ethics of Pharmacy Council of India in relation to the community and shall act as an integral part of health care team.

I shall uphold the laws and standards governing my profession.

I shall strive to perfect and enlarge my knowledge to contribute to the advancement of pharmacy and public health.

I shall follow the system, which I consider best for pharmaceutical care and counseling of patients.

I shall endeavour to discover and manufacture drugs of quality to alleviate sufferings of humanity.

I shall hold in confidence the knowledge gained about the patients in connection with professional practice and never divulge unless compelled to do so by the law.

I shall associate with organizations having their objectives for betterment of the profession of Pharmacy and make contribution to carry out the work of those organisations.

While I continue to keep this Oath inviolated, may it be granted to me to enjoy life and the practice of pharmacy respected by all, at all times!

Should I trespass and violate this oath, may the reverse bemy lot!

US District Court rules against Eli Lilly regarding Strattera patent

2010-08-13T21:43:00.000-07:00

Eli Lilly and Company announced that the US District Court for the District of New Jersey has ruled against the company in its patent litigation for Strattera (atomoxetine). In the case of Eli Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled that Lilly's '590 patent, or method-of-use patent, for Strattera is invalid. The patent had been set to expire in May of 2017.

"We disagree profoundly with the District Court's ruling and will appeal this decision," said Robert A. Armitage, senior vice president and general counsel for Lilly. "We continue to believe that our Strattera method-of-use patent should be found valid and should be upheld by the courts. The judge did not apply what we believe has been long-settled law on the legal issue of enablement. We will take every reasonable step to protect our intellectual property rights."

As a result of today's court decision, the company anticipates the near-term entry of generic atomoxetine in the US market. Although today's court decision will not cause the company to modify its current 2010 earnings per share guidance, the company does now expect revenue growth in the low- to mid-single digits, a reduction from its prior revenue growth guidance of mid-single digits.

"Although we are disappointed with today's ruling, we remain confident in our ability to execute on our strategy and in our long-term business prospects," said John Lechleiter, chairman and CEO. "Assuming a launch of a generic version of Strattera in the US, the loss of revenue will undoubtedly add to the challenges we will face during upcoming patent expirations on other key products. At the same time, we are taking the actions necessary to meet these challenges, including lowering our cost structure by at least $1 billion by the end of 2011 and reducing our full-time workforce. As a result, we still expect to generate sufficient cash flow in the coming years to fund research and development, make necessary capital investments and to pursue anticipated business development opportunities. In addition, we do not intend to deviate from our plan to maintain our dividend at least at its current level."

Lechleiter concluded, "We continue to be resolutely committed to our core strategy: accelerating the development of the promising molecules now in our labs. In addition to a diverse portfolio of medicines currently on the market, we have a robust pipeline of nearly 70 potential new medicines in clinical development, targeting areas such as diabetes, cancer, Alzheimer's disease and other unmet medical needs. The promise of this pipeline bodes well for Lilly and the patients we serve."

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.

2010-07-30T10:52:00.000-07:00

Pharmacists Oath

I Swear by the code of Ethics of Pharmacy Council of India in relation to the community and shall act as an integral part of health care team.

I shall uphold the laws and standards governing my profession.

I shall strive to perfect and enlarge my knowledge to contribute to the advancement of pharmacy and public health.

I shall follow the system, which I consider best for pharmaceutical care and counseling of patients.

I shall endeavour to discover and manufacture drugs of quality to alleviate sufferings of humanity.
I shall hold in confidence the knowledge gained about the patients in connection with professional practice and never divulge unless compelled to do so by the law.

I shall associate with organizations having their objectives for betterment of the profession of Pharmacy and make contribution to carry out the work of those organisations.

While I continue to keep this Oath inviolated, may it be granted to me to enjoy life and the practice of pharmacy respected by all, at all times!

Should I trespass and violate this oath, may the reverse bemy lot!